This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Dapagliflozin/saxagliptin" – news · newspapers · books · scholar · JSTOR (July 2020) (Learn how and when to remove this message)

Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.^[2][3] It is a combination of dapagliflozin and saxagliptin.^[2][3] It is taken by mouth.^[2][3]

The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).^[3]

Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.^[3][4]

In the United States, dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.^[2]

In the European Union, it is indicated in adults aged 18 years and older with type 2 diabetes:

• to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control.^[3]
• when already being treated with saxagliptin and dapagliflozin.^[3]